# First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

> **NCT02675465** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Pompe Disease

## Interventions

- **DRUG:** ATB200
- **DRUG:** AT2221

## Key facts

- **NCT ID:** NCT02675465
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675465, "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02675465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*